NCT06116968

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Corxel Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

Conditions

• Obstructive Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	Aficamten	5-20mg

Timeline

• Start date: 2023-11-14
• Primary completion: 2025-10-20
• Completion: 2025-10-20
• First posted: 2023-11-03
• Last updated: 2026-01-21

Locations

12 sites across 1 country: China